/
NVNO
$11.05+$0.21 (+1.94%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$7.2M
1M shares
52-week range
$8.67 – $196.70
1% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
1.67%
Moderate
Price (6 mo)
Loading chart…
Change$-347.35
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $186.6K | $31.2K | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $384.0K | $452.9K | $525.0K | $546.0K | $528.0K | $0 |
| Gross profit | $186.6K | $31.2K | −$384.0K | −$452.9K | −$525.0K | −$546.0K | −$528.0K | $0 |
| Gross margin | 100.0% | 100.0% | — | — | — | — | — | — |
| R&D | $1.2M | $2.2M | $4.3M | $5.7M | $9.9M | $13.6M | $12.2M | $10.0M |
| Operating income | −$7.9M | −$7.7M | −$9.1M | −$16.9M | −$24.9M | −$25.2M | −$23.8M | −$20.9M |
| EBITDA | −$6.0M | −$7.2M | −$8.8M | −$16.1M | −$24.1M | −$23.0M | −$21.3M | −$19.0M |
| Net income | −$13.0M | −$7.6M | −$9.1M | −$16.5M | −$24.7M | −$23.5M | −$21.8M | −$19.5M |
| Net margin | -6991.5% | -24406.7% | — | — | — | — | — | — |
| EPS (diluted) | -53495.75 | -14822.50 | -9236.50 | -2327.50 | -2695.00 | -2339.75 | -1555.75 | -33.06 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $7M | $-35.00 | $-35.00–$-35.00 | 1 |
| 2027 | $17M | $-25.90 | $-25.90–$-25.90 | 1 |
| 2028 | $29M | $-16.45 | $-16.45–$-16.45 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$3.46
Price
$11.05
Implied downside
-69%
Peer comparison
enVVeno Medical Corporation Common Stock
enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.
www.envveno.com- Employees
- 33
- IPO / List date
- May 31, 2018
- HQ
- IRVINE, CA
Held by traders on TradeandTell
No one on the platform currently holds NVNO.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in NVNO as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-01-20 | 1-for-35reverse |
| 2020-11-30 | 1-for-25reverse |
Recent trades on TradeandTell
No one on the platform has traded NVNO yet.
